GSK Buys Aiolos Bio for Up to $1.4 Billion -- Update
January 09 2024 - 3:04AM
Dow Jones News
By Christian Moess Laursen
GSK said it bought biopharmaceutical company Aiolos Bio for an
upfront consideration of $1.0 billion and the potential for an
additional $400 million, the latest in a string of pharmaceutical
majors buying fast-growing biotechs to restock their pipelines.
The British pharmaceutical giant said Tuesday that the deal to
buy San Francisco and London-based Aiolos Bio, which focuses on
patients with respiratory and inflammatory conditions, includes a
Phase 2-ready antibody called AIO-001 for the treatment of adult
patients with certain respiratory and inflammatory conditions.
The portfolio addition "could expand the reach of our current
respiratory biologics portfolio, to the 40% of severe asthma
patients with low type 2 inflammation where treatment options are
still needed," Chief Scientific Officer Tony Wood said.
The additional payment of up to $400 million is dependent on
certain regulatory milestones being met, it said.
Write to Christian Moess Laursen at christian.moess@wsj.com
(END) Dow Jones Newswires
January 09, 2024 02:49 ET (07:49 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Oct 2024 to Nov 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Nov 2023 to Nov 2024
